Đang chuẩn bị liên kết để tải về tài liệu:
Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Triple negative breast cancer (TNBC) is a distinct subtype of breast cancer burdened with a dismal prognosis due to the lack of effective therapeutic agents. Receptors for LHRH (luteinizing hormone-releasing hormone) can be successfully targeted with AEZS-108 [AN-152], an analog of LHRH conjugated to doxorubicin. |

TÀI LIỆU LIÊN QUAN

L1CAM is expressed in triple-negative breast cancers and is inversely correlated with Androgen receptor

Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers

The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: Possible link to disease early lesion

The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer

Identification of BRCA1-like triple-negative breast cancers by quantitative multiplexligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: A validation study

Molecular mechanism of anti-cancer activity of phycocyanin in triple-negative breast cancer cells

High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers

Downregulation of Smurf2, a tumor-suppressive ubiquitin ligase, in triple-negative breast cancers: Involvement of the RB-microRNA axis

Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival

RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage